<bill session="119" type="h" number="1405" updated="2025-07-09T14:00:49Z">
  <state datetime="2025-02-18">REFERRED</state>
  <status>
    <introduced datetime="2025-02-18"/>
  </status>
  <introduced datetime="2025-02-18"/>
  <titles>
    <title type="display">Enhancing Domestic Drug Manufacturing Competitiveness Act</title>
    <title type="short" as="introduced">Enhancing Domestic Drug Manufacturing Competitiveness Act</title>
    <title type="official" as="introduced">To direct the Comptroller General of the United States to conduct a study to assess the key regulatory barriers that impede the expansion or siting of new pharmaceutical manufacturing facilities in the United States, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="B001260"/>
  <cosponsors>
    <cosponsor bioguide_id="D000032" joined="2025-02-18"/>
  </cosponsors>
  <actions>
    <action datetime="2025-02-18">
      <text>Introduced in House</text>
    </action>
    <action datetime="2025-02-18" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referred To"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
    <term name="Administrative law and regulatory procedures"/>
    <term name="Congressional oversight"/>
    <term name="Environmental regulatory procedures"/>
    <term name="Government studies and investigations"/>
    <term name="Manufacturing"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
</bill>
